Synchron’s brain computer interface (BCI) device caused no deaths or permanent increases in disability in the first year of a U.S. clinical trial, the company said Monday. The study enrolled six ...
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Synchron has raised $200 million to support ...
Researchers monitored participants for one year and found the device to be safe, with no serious adverse events that led to disability or death. Stentrode™ also stayed in place for all four patients ...
The early feasibility study (EFS), funded by the National Institutes of Health (NIH), will primarily assess safety and begin to explore quantified efficacy measures of Synchron’s Stentrode™ in ...
Brain-computer interfaces, like Synchron's Stentrode device, could empower millions of disabled people to more easily communicate and engage in modern life Author of the article: You can save this ...
Stentrode is the only implantable brain-computer interface that does not require open brain surgery and is currently in clinical trials Synchron, a neurovascular bioelectronics medicine company, today ...
Medical device leaders who have built and scaled category-defining products join Synchron to help drive its next-generation brain-computer interface platform as well as accelerate towards ...
Brain-computer interface technology uses the fact that the brain communicates with itself and with the outside world using electrical signals. And so brain-computer interfaces are implants that use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results